Washington Post |
September 7th, 2008 |
Email this
As a senior executive at Adams Respiratory Therapeutics, John S. Thievon tackled the challenge of launching a pricey decongestant in a marketplace filled with cheap generics. Ultimately that drug, Mucinex, trampled its competition.[...]
Reckitt Benckiser has cut 100 jobs in five months at its new US healthcare business, Adams Respiratory Therapeutics[...]
Pharmatimes |
December 11th, 2007 |
Email this
Reckitt Benckiser has set its sights on expanding its consumer health presence in the USA, with a move to buy speciality pharmaceutical group Adams Respiratory Therapeutics for $2.3 billion.[...]
Financial Times |
December 10th, 2007 |
Email this
Reckitt Benckiser, the UK household goods maker, yesterday agreed to buy Adams Respiratory Therapeutics, a small US pharmaceuticals group, for £1.1bn ($2.3bn) as[...]
Business Week |
December 10th, 2007 |
Email this
Monday's stocks in the news[...]
Financial Times |
December 10th, 2007 |
Email this
Reckitt Benckiser, the UK household goods maker, agreed to buy Adams Respiratory Therapeutics, a small US pharmaceutical group, for $2.3bn as it outlined plans to build a global empire in over-the-counter drugs[...]
Business Week |
December 10th, 2007 |
Email this
Monday's stocks in the news[...]
Sure, the walking, talking gob of phlegm (pictured) was genius. But it was a clever intellectual property strategy that made that loogie worth $2.3 billion. That's how much British conglomerate Reckitt Benckiser just agreed to pay for Adams Respiratory Therapeutics, the maker of the cough medicine Mucinex (and sponsor of [...]
Reckitt Benckiser agreed to buy specialty pharmaceutical company Adams Respiratory Therapeutics, maker of Mucinex, for $2.3 billion, giving the British conglomerate entry into the U.S. health-care market.[...]
